Financial Performance - The company's revenue for Q3 2023 was ¥395,206,072.29, a decrease of 11.55% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥11,876,663.64, representing a decline of 290.80% year-on-year[4] - The basic earnings per share for Q3 2023 was -¥0.0058, down 293.33% from the previous year[4] - Total operating revenue for Q3 2023 reached CNY 1,445,366,591.95, an increase of 9.7% compared to CNY 1,317,388,175.56 in the same period last year[20] - Net profit for Q3 2023 was CNY 23,962,311.35, a decrease of 20.5% from CNY 30,294,249.44 in Q3 2022[21] - The company reported a profit before tax of CNY 41,306,414.75, down from CNY 49,091,648.83, indicating a decline of 16.5% year-over-year[21] - Other comprehensive income after tax for Q3 2023 was CNY 53,865,324.86, down from CNY 182,718,966.97, a decrease of 70.5%[21] - The company reported a total comprehensive income of CNY 77,827,636.21, significantly lower than CNY 213,013,216.41 in the same quarter last year, a decline of 63.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,524,396,567.87, a decrease of 5.66% from the end of the previous year[4] - As of September 30, 2023, the total current assets decreased to CNY 1,694,957,760.50 from CNY 2,091,204,367.56 at the beginning of the year, representing a decline of approximately 19%[17] - Total assets decreased to CNY 5,524,396,567.87 from CNY 5,855,659,382.96, a decline of 5.6%[19] - Total liabilities decreased to CNY 457,593,401.69 from CNY 804,568,205.38, a significant reduction of 43.2%[19] - The company's equity attributable to shareholders increased to CNY 5,082,273,045.39 from CNY 5,050,820,622.25, reflecting a slight increase of 0.6%[19] Cash Flow - The cash flow from operating activities showed a net outflow of ¥22,633,088.26, a decline of 115.44% compared to the same period last year[4] - Cash inflow from operating activities totaled ¥1,784,411,604.43, compared to ¥1,751,104,138.59 in the previous year, showing a slight increase[22] - Net cash flow from operating activities was negative at -¥22,633,088.26, a significant decline from a positive ¥146,603,775.86 in the same period last year[22] - Cash outflow from investing activities was ¥921,044,133.51, down from ¥1,541,502,268.40 in the previous year, indicating a reduction in investment spending[24] - Net cash flow from investing activities was -¥96,757,309.29, an improvement from -¥488,845,880.31 in Q3 2022[24] - Cash inflow from financing activities was ¥115,550,895.10, compared to ¥276,749,600.00 in the previous year, reflecting a decrease in financing received[24] - Net cash flow from financing activities was -¥236,070,256.85, a decline from a positive ¥11,612,877.84 in Q3 2022[24] - The ending balance of cash and cash equivalents was ¥275,147,122.98, down from ¥290,564,168.45 at the end of Q3 2022[24] - The company reported a total cash outflow of ¥357,793,276.38 for the quarter, compared to an outflow of ¥311,006,577.20 in the same period last year[24] Research and Development - The company has made progress in drug formulation research, achieving consistency evaluation for several products, which is expected to positively impact future sales[14] - The company applied for 2 new invention patents related to lithium carbonate and aminophylline during the third quarter[15] - The company is in the process of conducting bioequivalence trials for its heart failure drug formulations[15] - The company continues to focus on the integration of raw materials and formulations, utilizing biosynthesis technology for the development of biosimilars[15] Market and Operational Changes - The company reported a significant increase in prepayments by 79.12%, amounting to ¥15,105.16, due to expanded raw material procurement[8] - The company experienced a 31.72% increase in selling expenses, totaling ¥8,943.15, attributed to enhanced market expansion efforts for new auxiliary products[10] - Investment income increased by 542.67% to ¥1,898.82, primarily due to forward foreign exchange contract settlements[10] - The company reported a 102.80% increase in other current assets, reaching ¥15,098.29, due to an increase in bank wealth management products[8] - The company is actively expanding its lithium carbonate supply chain, establishing branches in Nigeria and other countries to enhance resource utilization[15] Shareholder Information - The total number of common stock shareholders as of the report date was 43,902[13] - The largest shareholder, Shuai Fangwen, holds a 41.38% stake, with a total of 853,574,906 shares, of which 640,181,179 shares are pledged[13] Audit Status - The third quarter report was not audited, indicating that the financial figures are subject to further verification[25]

关于调整第五届董事会审计委员会委员的公告 证券代码：300267 证券简称：尔康制药 公告编号：2023-038 湖南尔康制药股份有限公司 二〇二三年十月二十日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）于 2023 年 10 月 20 日召开 第五届董事会第六次会议，审议通过了《关于调整第五届董事会审计委员会委员 的议案》，现将具体情况公告如下： 根据中国证监会发布的《上市公司独立董事管理办法》中"审计委员会成员 应当为不在上市公司担任高级管理人员的董事"的规定，公司董事会同意对第五 届董事会审计委员会委员进行调整，公司董事、总经理孙庆荣先生不再担任审计 委员会委员职务，董事会选举董事长帅放文先生为审计委员会委员，与谭雪先生 （召集人）、王军文先生共同组成公司第五届董事会审计委员会，任期自本次董 事会审议通过之日起至第五届董事会届满之日止。 湖南尔康制药股份有限公司 董 事 会 ...

第一章 总则 第一条 为完善湖南尔康制药股份有限公司(以下称"公司")治理结构，规范 公司运作及独立董事行为，强化对董事会、管理层的监督约束机制，更好地保护 全体股东特别是中小股东的合法权益，根据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2—创业板上市公司规范运 作》以及《公司章程》等法律法规及规范性文件的规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及公司 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行 独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券交 易所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与决策、 监督制衡、专业咨询作用，维护公司整体利益，保护中小股东合法权益。 第四条 公司独立董事占董事会成员的比例不得低于三分之 ...

证券代码：300267 证券简称：尔康制药 公告编号：2023-036 湖南尔康制药股份有限公司 第五届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第五届监事会第五次会议 于 2023 年 10 月 20 日以现场会议和通讯表决相结合的方式召开。本次会议的通 知于 2023 年 10 月 12 日以书面、邮件形式通知了全体监事。本次会议应参与表 决的监事 3 名，实际参与表决的监事 3 名，本次会议的通知、召开以及参会监事 人数均符合相关法律、法规、规则及《公司章程》的有关规定。 与会监事经过认真审议，形成如下决议： 一、审议通过了《2023 年第三季度报告》及其摘要 《2023 年第三季度报告》《2023 年第三季度报告披露提示性公告》具体内容 详见中国证监会选定信息披露网站。 经审核，监事会认为：公司 2023 年第三季度报告及其摘要的编制程序符合 法律、行政法规和中国证监会的规定，内容真实、准确、完整反映了公司的实际 情况，不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果：同意 ...

第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第五届董事会第六次会议于 2023 年 10 月 20 日以现场会议和通讯表决相结合的方式召开。本次会议的通知 于 2023 年 10 月 12 日以书面、邮件形式通知了全体董事。本次会议应参与表决 的董事 7 名，实际参与表决的董事 7 名，本次会议的通知、召开以及参与人数均 符合相关法律、法规、规则及《公司章程》的有关规定。 经全体董事认真审议，形成如下决议： 一、审议通过了《2023 年第三季度报告》 证券代码：300267 证券简称：尔康制药 公告编号：2023-035 湖南尔康制药股份有限公司 二、审议通过了《关于调整第五届董事会审计委员会委员的议案》 根据中国证监会发布的《上市公司独立董事管理办法》中"审计委员会成员 应当为不在上市公司担任高级管理人员的董事"的规定，公司董事会同意对第五 届董事会审计委员会委员进行调整，公司董事、总经理孙庆荣先生不再担任审计 委员会委员职务，董事会选举董事长帅放文先生为审计委员会委员，与谭雪先 ...

证券代码：300267 证券简称：尔康制药 公告编号：2023-034 湖南尔康制药股份有限公司 关于氨茶碱注射液通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 产品名称 剂型 注册 分类 规格 药品批准 文号 药品注 册标准 编号 生产企业 审批结论 氨茶碱注 射液 注射剂 化学 药品 20ml:0. 5g 国药准字 H43020844 YBH153 02023 湖南尔康 制药股份 有限公司 根据《中华人民共和国药品管理 法》、《国务院关于改革药品医疗器 械审评审批制度的意见》（ 国发 〔2015〕44 号）、《关于仿制药质量 和疗效一致性评价工作有关事项 的公告》（2017 年第 100 号）和《国 家药监局关于开展化学药品注射 剂仿制药质量和疗效一致性评价 工作的公告》（2020 年第 62 号）的 规定，经审查，本品 20ml:0.5g、 10ml:0.25g 通过仿制药质量和疗 效一致性评价。同时同意以下变 更：1.变更药品规格和处方；2.变更 药品生产工艺；3.变更药品质量标 准；4.变更直接接触药品的包装材 料和容器。 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,050,160,519.66, representing a 20.63% increase compared to CNY 870,551,135.58 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 51,950,756.08, a significant increase of 72.66% from CNY 30,088,115.38 in the previous year[20]. - The basic earnings per share rose to CNY 0.0252, up 72.60% from CNY 0.0146 in the same period last year[20]. - The net cash flow from operating activities decreased by 24.55% to CNY 51,351,223.74, down from CNY 68,063,584.22 in the previous year[20]. - Total assets at the end of the reporting period were CNY 5,584,757,117.16, a decrease of 4.63% from CNY 5,855,659,382.96 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 1.06% to CNY 5,104,552,312.19 from CNY 5,050,820,622.25 at the end of the previous year[20]. - The company reported a total comprehensive income of ¥105,346,269.81 for the first half of 2023, compared to ¥113,587,349.90 in the previous year[164]. - The company reported a total profit of CNY 35,523,230.80, a decrease of 46.5% from CNY 66,624,805.91 in the previous year[167]. - The net profit for the first half of 2023 was ¥41,118,711.80, representing a 51.5% increase from ¥27,145,571.92 in the first half of 2022[163]. Revenue and Sales - The company achieved operating revenue of CNY 1,050.16 million, a year-on-year increase of 20.63%[32]. - The sales revenue from composite excipients amounted to 424.85 million yuan in the first half of 2023[43]. - The lithium carbonate and its preparations project entered trial production, generating sales revenue of 8.20 million yuan[43]. - Total revenue from sales of goods and services reached CNY 1,028,592,895.83, an increase of 23.8% from CNY 837,556,541.23 in the first half of 2022[170]. - The company's operating revenue for the pharmaceutical sector reached ¥1,029,360,323.29, representing an 18.98% increase compared to the same period last year[55]. Costs and Expenses - The company's operating costs increased by 19.86% to ¥785,439,197.64, primarily due to intensified market expansion efforts[52]. - The company's sales expenses increased by 70.65% to ¥67,516,427.13, reflecting increased marketing efforts[52]. - The financial expenses for the first half of 2023 were ¥4,053,517.86, an increase from ¥3,062,302.27 in the same period of 2022[163]. - The company experienced a significant increase in sales expenses, which rose to ¥67,516,427.13 in the first half of 2023 from ¥39,564,099.62 in the previous year, reflecting a growth of 70.7%[163]. Assets and Liabilities - Total assets of Hunan Erkang Pharmaceutical reached 962,716,330 CNY, with net assets amounting to 843,866,030 CNY[78]. - The company's total liabilities decreased to ¥966,954,345.05 in the first half of 2023 from ¥1,208,139,685.74 in the same period of 2022, a reduction of approximately 19.96%[163]. - Total current assets decreased from CNY 2,091,204,367.56 to CNY 1,758,508,679.43, a decline of approximately 15.9%[155]. - Total liabilities decreased from CNY 804,568,205.38 to CNY 490,303,305.70, a reduction of about 39.0%[157]. - Short-term borrowings significantly reduced from CNY 396,641,418.80 to CNY 149,000,000.00, a decrease of approximately 62.5%[157]. Investments and Projects - The company has increased its investment in new projects, with construction in progress rising by 224.45% to ¥171,687,828.48[52]. - The company invested 1 billion in the construction of lithium carbonate and its formulation project, which has already achieved product sales primarily for industrial use[129]. - The company is actively pursuing resource negotiations and project site selection for its new energy initiatives[130]. - The company has committed to investing in bank wealth management products totaling 12,100,000, with an outstanding balance of 6,100,000[70]. Market and Industry Trends - The pharmaceutical industry is undergoing significant reforms, with over 100 key policies released by various ministries by June 2023, impacting market dynamics[33]. - The pharmaceutical manufacturing industry saw a decline in revenue of 2.9% year-on-year, totaling CNY 1,249.6 billion in the first half of 2023[34]. - The demand for lithium batteries in the energy storage sector surged, with a 67% year-on-year increase in lithium battery shipments in the first half of 2023[36]. - The sales volume of new energy vehicles in China reached 3.747 million units in the first half of 2023, marking a 44.1% year-on-year growth[36]. Risk Management - The company has emphasized the importance of risk awareness regarding forward-looking statements in the report[4]. - The company is facing risks from raw material price fluctuations due to macroeconomic factors, and it aims to strengthen market monitoring and analysis to mitigate these risks[83]. - The company has developed a hedging management system to address foreign exchange risks associated with its increased demand for bulk raw materials[84]. - The company has established a comprehensive risk management system for its foreign exchange hedging activities, ensuring compliance with legal regulations[73]. Environmental Responsibility - The company is recognized as a key pollutant discharge unit by environmental protection authorities, with its latest discharge permit valid for five years[95]. - Xiangyikang has constructed a wastewater treatment plant with a daily capacity of 900 tons, operating normally with no exceedance of discharge limits[96]. - Total environmental protection expenditure for the first half of 2023 amounted to 5.9333 million yuan, with 2.4992 million yuan allocated to environmental engineering[100]. - The company has implemented a self-monitoring plan for environmental compliance, with monthly third-party testing of wastewater and air emissions[98]. Corporate Governance - The company has no significant related party transactions during the reporting period[113]. - The financial report for the first half of 2023 has not been audited[153]. - The company has no significant changes in the measurement attributes of its major assets during the reporting period[64]. - The company has not reported any overdue or unrecoverable amounts related to entrusted financial management[71].

一、独立董事关于2023年半年度公司关联方资金占用情况及对外担保情况的 独立意见 1、2023年上半年，公司不存在控股股东及其他关联方违规占用公司资金的 情况。 湖南尔康制药股份有限公司 独立董事关于相关事项的独立意见 根据《公司法》、《上市公司独立董事规则》、《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》等法律法规以及湖南尔康制药股 份有限公司（以下简称"公司"）《公司章程》的有关规定，我们作为公司的独立董 事，基于独立判断的立场，本着对公司、全体股东负责的态度，秉持实事求是的 原则，对2023年半年度公司关联方资金占用情况及对外担保情况、公司开展商品 期货套期保值业务事项进行了认真核查，发表独立意见如下： 二、独立董事关于公司开展商品期货套期保值业务的独立意见 公司开展商品期货套期保值业务是在保证正常生产经营的前提下，根据市场 情况，利用商品期货套期套期保值功能，合理规避主要原材料及产成品价格波动 风险，有利于提升公司风险抵御能力，促进公司稳健经营。公司开展商品期货套 期保值业务的相关审批程序合规，内部控制程序健全，符合国家相关法律、法规 及《公司章程》的有关规定，不存在损害公司 ...

证券代码：300267 证券简称：尔康制药 公告编号：2023-033 湖南尔康制药股份有限公司 关于 2023 年半年度计提和转回减值损失 以及核销资产的公告 根据相关法律法规要求，为真实准确地反映公司截至2023年半年度的财务 状况、资产价值和经营情况，基于谨慎性原则，公司对合并报表范围内的各类 资产进行了全面清查，对各项资产减值的可能性进行了充分的评估和分析，对 截至2023年6月30日合并报表范围内有关资产计提和转回相应减值损失。 二、本次计提和转回减值损失以及核销资产的范围和金额 2023年1-6月公司计提减值损失282.46万元、转回减值损失1,297.79万元， 核销/转销资产5,427.28万元，汇率变动的影响20.55万元，期末资产减值准备余 额10,286.36万元。具体明细如下： 单位：万元 | 类别 | 项目 | 期初余额 | 计提 | 转回 | 核销/转销 | 汇率变动 | 期末余额 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 的影响 | | | 信用减值 | 应收账款坏 账准备 | 5,791. ...

证券代码：300267 证券简称：尔康制药 公告编号：2023-032 湖南尔康制药股份有限公司 公司于2023年8月25日召开第五届董事会第五次会议、第五届监事会第四次 会议，审议通过了《关于开展商品期货套期保值业务的议案》，现将具体内容 公告如下： 一、开展商品期货套期保值业务的目的 关于开展商品期货套期保值业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、交易目的：湖南尔康制药股份有限公司及子公司（以下简称"公司"）拟 利用商品期货套期保值功能，合理规避主要原材料及产成品价格波动风险，降 低价格波动对生产经营的影响，提升风险抵御能力，增强财务稳健性。 2、交易场所及品种：限于在场内市场交易的与公司的生产经营有直接关系 的期货品种。 3、交易金额：2023年度开展商品期货套期保值业务占用的保证金最高额度 不超2,000万元人民币（不含期货标的实物交割款项），上述额度在2023年度可 循环使用。 4、审议程序：本次商品期货套期保值业务已经公司第五届董事会第五次会 议、第五届监事会第四次会议审议通过。根据相关法律法规，本次开展商品 ...